SEC Form 4 · accession 0001250853-17-000060
Kindred Biosciences, Inc. · KIN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard Chin
Officer — President and CEO · Director · 10% Owner
Period of report
Jul 3, 2017
Accepted (ET)
Jul 6, 2017 · 5:50 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001561743
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 3, 2017 | S | 13,000 | $8.26 | D | 2,297,546 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.15 to $8.65, inclusive. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 23, 2017.